6 on a current fund
last 24 months
across filed funds
| Vehicle | Filed | Target | Sold to date | Investors |
|---|---|---|---|---|
| Vivo Innovation Fund II, L.P. | February 2021 | Indefinite | $180M | 11 |
| Vivo Innovation Fund II Associates, L.P.Filed to raise in 2021, with no closing reported yet. | 2021 | Indefinite | $0 | 0 |
Amounts are Item 13 as filed: the target is the whole offering, and the amount sold is cumulative across amendments rather than a final close. The filing carries no per-investor amount, so a firm’s own cheque is not recoverable here.
6 partners are named across this firm’s filings, 6 of them on a fund it is deploying now.
| Partner | Activity | Categories | Board seats | Last 24mo |
|---|---|---|---|---|
| Michael Chang | Slowing | Healthcare services, Biotech & pharma, Food & agriculture | 13 |
Classified sectors of Vivo Innovation’s own portfolio companies, based on 33 with a verified or cited source.
| Firm | Shared boards | Companies |
|---|---|---|
| Vivo Capital | 33 | AEMS, Aligos Therapeutics, ALIOS BIOPHARMA, AMYRIS, ANSUN BIOPHARMA, BioClin Therapeutics, Bolt Biotherapeutics, Capnia, Crinetics Pharmaceuticals, EIGER BIOPHARMACEUTICALS, Eiger BioPharmaceuticals, Frontier Nutrition, Harmony Biosciences II, Hera Holdco, Hera Physician Holdco, Hera Topco, InDevR, Inspirna, Instil Bio, Kanyos Bio, MacuLogix, ManaT Bio, MBio Diagnostics, Merus N.V., NJ Nectar Management, Nutex Health, Ocelot Bio, PROCEPT BioRobotics, REATA PHARMACEUTICALS, SWNB BANCORP, Unchained Labs, USA Baldwin County ASC, YESVIDEO |
| Sofinnova Venture Partners | 2 | Bolt Biotherapeutics, Merus N.V. |
| Versant Vantage |
| 1 |
| DanDan Dong | Quiet | None listed | 0 | 0 |
| Edgar Engleman | Quiet | Biotech & pharma, Medical devices | 4 | 0 |
| Frank Kung | Quiet | Biotech & pharma | 1 | 0 |
| Jack Nielsen | Quiet | Biotech & pharma, Medical devices | 16 | 0 |
| Lu Hongbo | Quiet | None listed | 0 | 0 |
Activity is filed board seats in the last 24 months: 4+ Active, 2–3 Selective, 1 Slowing, none Quiet. A firm's tier totals its partners, so an active firm may be four partners with one seat each. It undercounts partners who invest without taking a board seat, and filings lag a closing by weeks, so Quiet means the paperwork is quiet, not the person.
Not a filing value: this is Lev’s own classification of each company, one company one vote regardless of how many of Vivo Innovation’s partners are named on its board, shown only when we found a specific, checkable source. Companies with no source read as unclassified and are left out of the shares above.
| 2 |
| Aligos Therapeutics, Kanyos Bio |
| Versant Venture Capital | 2 | Aligos Therapeutics, Kanyos Bio |
| Versant Venture V AIV | 2 | Aligos Therapeutics, Kanyos Bio |
| Versant Voyageurs | 2 | Aligos Therapeutics, Kanyos Bio |
| Capra CLO Founders | 1 | Bolt Biotherapeutics |
| CV Consortio | 1 | Harmony Biosciences II |
| Khosla Ventures | 1 | AMYRIS |
| MPM BioVentures | 1 | Aligos Therapeutics |
| Pivotal bioVenture Partners | 1 | Bolt Biotherapeutics |
| Third Rock Ventures | 1 | ManaT Bio |
| Valor Equity Partners | 1 | Harmony Biosciences II |
| Valor Siren Ventures | 1 | Harmony Biosciences II |
A shared board seat: a company where filings name a Vivo Innovation partner and a partner at the other firm, both with a clean identity match. Not a claim either firm led or co-led the round, only that both are named on the same board.
